Soleno Therapeutics, Inc. (SLNO) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $53.01 (—)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 4, 2026 | Raghuram Selvaraju | H.C. Wainwright | $100.00 | +88.6% |
| Jan 20, 2026 | Derek Archila | Wells Fargo | $114.00 | +115.1% |
| Nov 5, 2025 | Derek Archila | Wells Fargo | $106.00 | +100.0% |
| Jul 11, 2025 | Brian Skorney | Robert W. Baird | $121.00 | +128.3% |
| Mar 28, 2025 | Debjit Chattopadhyay | Guggenheim | $81.00 | +52.8% |
| Dec 2, 2024 | Raghuram Selvaraju | H.C. Wainwright | $70.00 | +32.1% |
| Oct 1, 2024 | Dae Gon Ha | Stifel Nicolaus | $74.00 | +39.6% |
| Aug 27, 2024 | Dae Gon | Stifel Nicolaus | $59.00 | +11.3% |
| Aug 27, 2024 | Leland Gershell | Oppenheimer | $65.00 | +22.6% |
| May 23, 2024 | Yasmeen Rahimi | Piper Sandler | $93.00 | +75.4% |
| May 9, 2024 | Brian Skorney | Robert W. Baird | $72.00 | +35.8% |
Top Analysts Covering SLNO
SLNO vs Sector & Market
| Metric | SLNO | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.45 | 2.24 | 2.40 |
| Analyst Count | 11 | 8 | 19 |
| Target Upside | +50.9% | +11475.0% | +17.1% |
| P/E Ratio | 30.01 | 3.88 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $117M | $123M | $135M | 4 |
| 2026-12-31 | $130M | $138M | $151M | 4 |
| 2027-03-31 | $146M | $154M | $169M | 4 |
| 2027-06-30 | $163M | $172M | $188M | 3 |
| 2027-09-30 | $174M | $184M | $201M | 3 |
| 2027-12-31 | $191M | $202M | $221M | 3 |
| 2028-03-31 | $778M | $820M | $898M | 2 |
| 2028-06-30 | $87M | $92M | $100M | 5 |
| 2028-12-31 | $985M | $985M | $985M | 7 |
| 2029-12-31 | $1.10B | $1.28B | $1.45B | 3 |
| 2030-12-31 | $1.34B | $1.55B | $1.76B | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $0.99 | $1.06 | $1.19 | 3 |
| 2026-12-31 | $1.19 | $1.28 | $1.44 | 7 |
| 2027-03-31 | $1.21 | $1.29 | $1.45 | 3 |
| 2027-06-30 | $1.50 | $1.61 | $1.80 | 3 |
| 2027-09-30 | $1.64 | $1.76 | $1.97 | 4 |
| 2027-12-31 | $1.90 | $2.04 | $2.29 | 3 |
| 2028-03-31 | $6.83 | $7.33 | $8.23 | 4 |
| 2028-06-30 | $6.83 | $7.33 | $8.23 | 4 |
| 2028-12-31 | $4.72 | $8.67 | $13.23 | 7 |
| 2029-12-31 | $8.75 | $10.68 | $12.54 | 2 |
| 2030-12-31 | $10.77 | $13.15 | $15.43 | 5 |
Frequently Asked Questions
What is the analyst consensus for SLNO?
The consensus among 11 analysts covering Soleno Therapeutics, Inc. (SLNO) is Buy with an average price target of $80.00.
What is the highest price target for SLNO?
The highest price target for SLNO is $121.00, set by Brian Skorney at Robert W. Baird on 2025-07-11.
What is the lowest price target for SLNO?
The lowest price target for SLNO is $59.00, set by Dae Gon at Stifel Nicolaus on 2024-08-27.
How many analysts cover SLNO?
11 analysts have issued ratings for Soleno Therapeutics, Inc. in the past 12 months.
Is SLNO a buy or sell right now?
Based on 11 analyst ratings, SLNO has a consensus rating of Buy (2.45/5) with a +50.9% upside to the consensus target of $80.00.
What are the earnings estimates for SLNO?
Analysts estimate SLNO will report EPS of $1.06 for the period ending 2026-09-30, with revenue estimated at $123M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.